Harrow Stock Tumbles on Weaker 1Q Revenue, Wider Loss

Dow Jones05-12

By Dean Seal

Shares of Harrow fell after a surge in demand from high-deductible patients for one of its key products hurt revenue and earnings in the first quarter.

The stock dropped 20% to $30.32 on Tuesday. Shares are now down 39% year to date.

The biotech company said revenue declined 7.6% to $44.2 million in the first quarter. Analysts polled by FactSet had been expecting a gain to $52.4 million.

Weaker gross margins on those sales widened the company's quarterly loss to $27.6 million, or 74 cents a share, from a loss of $17.8 million, or 50 cents a share, a year earlier. Analysts had expected the shortfall to narrow to 40 cents a share.

Chief Executive Mark Baum said demand for Harrow's flagship products was strong, but commercial coverage for its prescription eye-drop Vevye wound up hurting the bottom line. A higher-than-expected number of patients with high-deductible insurance plans bought Vevye, spurring the company to provide more out-of-pocket coupons and assistance than initially planned.

Harrow has since adjusted its rules to resolve the issue, Baum said. "With these rules now in place, we are now positioned to realize the expected financial benefit of our expanded commercial access," he said.

Write to Dean at dean.seal@wsj.com

(END) Dow Jones Newswires

May 12, 2026 11:53 ET (15:53 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634245916?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 23:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634245916","market":"hk","top_or_hot":-1,"title":"Harrow Stock Tumbles on Weaker 1Q Revenue, Wider Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Harrow fell after a surge in demand from high-deductible patients for one of its key products hurt revenue and earnings in the first quarter. \n</p>\n<p>\n  The stock dropped 20% to $30.32 on Tuesday. Shares are now down 39% year to date. \n</p>\n<p>\n  The biotech company said revenue declined 7.6% to $44.2 million in the first quarter. Analysts polled by FactSet had been expecting a gain to $52.4 million. \n</p>\n<p>\n  Weaker gross margins on those sales widened the company's quarterly loss to $27.6 million, or 74 cents a share, from a loss of $17.8 million, or 50 cents a share, a year earlier. Analysts had expected the shortfall to narrow to 40 cents a share. \n</p>\n<p>\n  Chief Executive Mark Baum said demand for Harrow's flagship products was strong, but commercial coverage for its prescription eye-drop Vevye wound up hurting the bottom line. A higher-than-expected number of patients with high-deductible insurance plans bought Vevye, spurring the company to provide more out-of-pocket coupons and assistance than initially planned. \n</p>\n<p>\n  Harrow has since adjusted its rules to resolve the issue, Baum said. \"With these rules now in place, we are now positioned to realize the expected financial benefit of our expanded commercial access,\" he said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 12, 2026 11:53 ET (15:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harrow Stock Tumbles on Weaker 1Q Revenue, Wider Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarrow Stock Tumbles on Weaker 1Q Revenue, Wider Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-12 23:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Harrow fell after a surge in demand from high-deductible patients for one of its key products hurt revenue and earnings in the first quarter. \n</p>\n<p>\n  The stock dropped 20% to $30.32 on Tuesday. Shares are now down 39% year to date. \n</p>\n<p>\n  The biotech company said revenue declined 7.6% to $44.2 million in the first quarter. Analysts polled by FactSet had been expecting a gain to $52.4 million. \n</p>\n<p>\n  Weaker gross margins on those sales widened the company's quarterly loss to $27.6 million, or 74 cents a share, from a loss of $17.8 million, or 50 cents a share, a year earlier. Analysts had expected the shortfall to narrow to 40 cents a share. \n</p>\n<p>\n  Chief Executive Mark Baum said demand for Harrow's flagship products was strong, but commercial coverage for its prescription eye-drop Vevye wound up hurting the bottom line. A higher-than-expected number of patients with high-deductible insurance plans bought Vevye, spurring the company to provide more out-of-pocket coupons and assistance than initially planned. \n</p>\n<p>\n  Harrow has since adjusted its rules to resolve the issue, Baum said. \"With these rules now in place, we are now positioned to realize the expected financial benefit of our expanded commercial access,\" he said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 12, 2026 11:53 ET (15:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634245916","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634245916","pubTimestamp":1778601180,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Harrow fell after a surge in demand from high-deductible patients for one of its key products hurt revenue and earnings in the first quarter.The stock dropped 20% to $30.32 on Tuesday. Shares are now down 39% year to date.The biotech company said revenue declined 7.6% to $44.2 million in the first quarter. Analysts polled by FactSet had been expecting a gain to $52.4 million.Weaker gross margins on those sales widened the company's quarterly loss to $27.6 million, or 74 cents a share, from a loss of $17.8 million, or 50 cents a share, a year earlier. Analysts had expected the shortfall to narrow to 40 cents a share.Chief Executive Mark Baum said demand for Harrow's flagship products was strong, but commercial coverage for its prescription eye-drop Vevye wound up hurting the bottom line. A higher-than-expected number of patients with high-deductible insurance plans bought Vevye, spurring the company to provide more out-of-pocket coupons and assistance than initially planned.Ha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc","BK4007":"制药","BK4557":"大麻股"},"translate_title":"哈罗股价因第一季度收入疲软和亏损扩大而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Harrow fell after a surge in demand from high-deductible patients for one of its key products hurt revenue and earnings in the first quarter. \n\n\n  The stock dropped 20% to $30.32 on Tuesday. Shares are now down 39% year to date. \n\n\n  The biotech company said revenue declined 7.6% to $44.2 million in the first quarter. Analysts polled by FactSet had been expecting a gain to $52.4 million. \n\n\n  Weaker gross margins on those sales widened the company's quarterly loss to $27.6 million, or 74 cents a share, from a loss of $17.8 million, or 50 cents a share, a year earlier. Analysts had expected the shortfall to narrow to 40 cents a share. \n\n\n  Chief Executive Mark Baum said demand for Harrow's flagship products was strong, but commercial coverage for its prescription eye-drop Vevye wound up hurting the bottom line. A higher-than-expected number of patients with high-deductible insurance plans bought Vevye, spurring the company to provide more out-of-pocket coupons and assistance than initially planned. \n\n\n  Harrow has since adjusted its rules to resolve the issue, Baum said. \"With these rules now in place, we are now positioned to realize the expected financial benefit of our expanded commercial access,\" he said. \n\n\n \n\n\n  Write to Dean at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 11:53 ET (15:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634245916","isCrawlerRequest":true}